Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and Zepbound tirzepatide therapy. All providers are board-certified and committed to evidence-based natural weight loss care.
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are hormones your body naturally produces after eating. They signal fullness, regulate appetite, and control energy processing. In many people with obesity, these natural signals are diminished — making it physiologically harder to feel satisfied and maintain a healthy weight.
Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist that simultaneously activates both of your natural hunger hormone pathways. This dual mechanism — amplifying what your body already does naturally — produces greater weight reduction than single GLP-1 activation alone. SURMOUNT-1 trials demonstrated 20.9–22.5% body weight reduction over 72 weeks.
Natural results require professional guidance. Our board-certified physicians prescribe personalized Zepbound protocols starting at the lowest available dose (2.5mg weekly) and titrating gradually based on your response and tolerance — making your weight loss journey as natural and comfortable as possible for your body.
Complete our online health intake to determine if Zepbound is right for your body. Our physicians evaluate your BMI (≥30, or ≥27 with a weight-related condition), medical history, current medications, and weight loss goals to determine your optimal Zepbound starting dose and natural titration schedule.
A board-certified physician prescribes your individualized Zepbound protocol — starting at 2.5mg weekly and increasing gradually to 5mg, 7.5mg, 10mg, 12.5mg, or 15mg based on your natural tolerance. The gentle escalation respects your body's adjustment process and minimizes early side effects.
Your Zepbound prescription ships from a licensed pharmacy to your door in 2–5 business days. Regular physician check-ins track your natural weight loss progress, monitor your body's response, and adjust your dose as you progress through your Zepbound journey.
Dual GIP/GLP-1 Agonist — FDA-Approved for Obesity
Zepbound is FDA-approved specifically for chronic weight management in adults with obesity or overweight with a weight-related condition. Its dual GIP/GLP-1 natural hormone activation achieves 22.5% average body weight reduction in SURMOUNT-1 (72 weeks). Available 2.5mg–15mg weekly, starting with the gentlest dose to allow natural adjustment.
Get Natural ZepboundSame Tirzepatide — Metabolic Health & Natural Weight Loss
Mounjaro uses the same tirzepatide compound as Zepbound, FDA-approved for type 2 diabetes with natural metabolic weight loss benefits. Some patients prefer Mounjaro for its metabolic health profile. Your physician will determine the most appropriate tirzepatide formulation for your natural health profile and clinical needs.
Explore Tirzepatide OptionsSingle Natural GLP-1 Pathway — 14.9% Weight Reduction
For patients who prefer single-pathway natural GLP-1 hormone activation, semaglutide (Ozempic®/Wegovy®) delivers clinically proven weight loss of 14.9% over 68 weeks. A well-established natural GLP-1 hormone amplifier with over 5 years of real-world data — also available through our platform.
Explore SemaglutideAdult obesity rates (CDC Behavioral Risk Factor Surveillance System, 2023) vary significantly across the United States. States with higher obesity prevalence experience the greatest demand for accessible GLP-1 telehealth prescriptions:
Source: CDC Behavioral Risk Factor Surveillance System (BRFSS) 2023. Adult obesity defined as BMI ≥ 30.0.
Our board-certified physicians prescribe Zepbound (tirzepatide) online in every US state. Select your state to find natural Zepbound program access near you.
Zepbound (tirzepatide) activates two hormones your body already produces naturally — GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These hormones are released after eating to signal fullness and regulate appetite. In people with obesity, these natural signals are often diminished. Zepbound restores and amplifies these natural hormonal pathways, making it a biologically aligned approach to sustainable weight loss.
Zepbound (tirzepatide) demonstrated the highest weight loss efficacy of any FDA-approved medication in the SURMOUNT-1 clinical trial. Participants achieved an average of 20.9% body weight reduction at 10mg and 22.5% at 15mg over 72 weeks. Over 90% of participants lost at least 5% of body weight. These results reflect the power of dual GIP/GLP-1 hormone activation — a more complete natural response than single-pathway GLP-1 therapy alone.
Zepbound is FDA-approved for adults with a BMI of 30 or higher (obesity), or a BMI of 27 or higher with at least one weight-related condition such as hypertension, type 2 diabetes, high cholesterol, or sleep apnea. Our board-certified physicians evaluate your eligibility through a comprehensive online health intake — no in-person visit required.
The most common Zepbound side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation — particularly during the initial dose escalation period. These reflect your body's natural adjustment to amplified GIP/GLP-1 signaling and typically improve after the first 4–8 weeks. Starting at the lowest dose (2.5mg) and escalating gradually minimizes these natural adjustment symptoms.
Most Zepbound patients notice reduced appetite within 1–2 weeks. Measurable weight loss typically begins within 4 weeks, with 5–8% body weight reduction by weeks 8–12. Significant transformation — 15–22% — occurs over 12–18 months. Your physician monitors your natural response throughout and adjusts dosing accordingly.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
Connect with experienced, US-licensed physicians specializing in metabolic health and Zepbound tirzepatide therapy. All providers are board-certified and committed to evidence-based natural weight loss care.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
